Logo
x

Search

Subscribe Now

Qilu Pharmaceutical

Qilu Pharmaceutical Reports Results from the P-II Trial of QL1706 for Non-Small Cell Lung Cancer (NSCLC)

Qilu Pharmaceutical Reports Results from the P-II Trial of QL1706 for Non-Small Cell Lung Cancer (NSCLC)

  • February 2, 2024
Qilu Pharmaceutical Presents P-II Study Results of QL1706 for the Treatment of Non-Small Cell Lung Cancer at ESMO 2022

Qilu Pharmaceutical Presents P-II Study Results of QL1706 for the Treatment of Non-Small Cell Lung Cancer at ESMO 2022

  • December 2, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.